8-K: Guardian Pharmacy Services Reports Strong Q4 and Full Year 2024 Financial Results, Exceeding Expectations

Guardian Pharmacy Services announces a 20% year-over-year revenue increase for Q4 2024 and a 17% increase for the full year, driven by organic growth and strategic acquisitions.

Summary

• Guardian Pharmacy Services reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Q4 revenue reached $338.6 million, a 20% increase year-over-year.
• This growth was fueled by organic expansion and the acquisitions of Heartland Pharmacy and Freedom Pharmacy.
• The resident count increased to 186,000, a 14% rise year-over-year.
• Net income for Q4 was $11.8 million, a decrease of $2.7 million year-over-year, attributed to changes in income tax provision expense, share-based compensation expense, and expenses related to legal and regulatory matters.
• Adjusted EBITDA for Q4 was $25.9 million, a 30% increase year-over-year, benefiting from organic growth and efficiencies in vaccine clinic administration.
• Full-year revenue reached $1.228 billion, a 17% increase year-over-year.
• The company reported a net loss of $71.0 million for the full year, primarily due to $131.5 million in share-based compensation expense related to the Corporate Reorganization and IPO.
• Adjusted EBITDA for the full year was $90.8 million, a 19% increase year-over-year.
• Guardian had no outstanding debt at year-end due to the IPO proceeds.
• The company has $40 million available under its line of credit, with the potential to increase it to $75 million.
• Initial full-year 2025 guidance projects revenue between $1.330 billion and $1.350 billion.
• Adjusted EBITDA for 2025 is projected to be between $97.0 million and $101.0 million, including $4.0 million in incremental public company expenses.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue and EBITDA growth, exceeding expectations. While there are some negative aspects like the net loss due to IPO-related expenses, the overall tone is optimistic and forward-looking.

Positives

• Strong revenue growth in both Q4 and the full year, driven by organic growth and acquisitions.
• Significant increase in resident count, indicating market expansion.
• Substantial growth in Adjusted EBITDA, reflecting improved operational efficiency.
• Elimination of outstanding debt and availability of a credit facility, providing financial flexibility.
• Positive outlook for 2025 with projected revenue and Adjusted EBITDA growth.

Negatives

• Decrease in net income for Q4 due to increased expenses.
• Net loss for the full year primarily due to share-based compensation expenses related to the IPO.
• Increased selling, general, and administrative expenses as a percentage of revenue.

Risks

• The company's ability to effectively execute its business strategies and implement new initiatives.
• Competition in the pharmaceutical services market.
• Changes in healthcare laws and regulations.
• The ability to retain key personnel.
• Potential cyber-attacks on operating and information technology systems.
• Product liability or recall issues related to dispensed pharmaceuticals.
• Volatility of the company's stock price.

Future Outlook

Guardian anticipates revenue between $1.330 billion and $1.350 billion and Adjusted EBITDA between $97.0 million and $101.0 million for the full year 2025, not including potential future M&A activity.

Management Comments

• Were proud to report that we ended the year on a strong note, exceeding our expectations for the fourth quarter and year ended December 31, 2024.
• Looking ahead, we enter 2025 well-positioned for success and we remain committed to continuing to meet the needs of all of the residents we serve, said Fred Burke, President & CEO of Guardian.

Industry Context

Guardian Pharmacy Services operates in the long-term care (LTC) pharmacy services market, which is influenced by factors such as the aging population, government regulations, and reimbursement policies. The company's growth through acquisitions and organic expansion reflects a strategy to consolidate market share in a competitive industry.

Comparison to Industry Standards

• CVS Health and Walgreens Boots Alliance also operate in the pharmacy services sector, but with a broader scope than just LTC.
• Omnicare, a CVS Health company, is a direct competitor in the LTC pharmacy space.
• Guardian's revenue growth of 17% for the year compares favorably to the overall growth rate of the pharmacy services market, which is typically in the single digits.
• The adjusted EBITDA margin of 7.4% for the full year is within the typical range for pharmacy services companies.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue and EBITDA growth.
• Employees may benefit from the company's continued success and expansion.
• Customers (LTC facilities and residents) can expect continued service and potential improvements.
• Suppliers may see increased demand due to the company's growth.
• Creditors benefit from the company's strong financial position and ability to meet its obligations.

Next Steps

• Guardian will host a conference call on March 26, 2025, to discuss the financial results.
• The company will continue to focus on organic growth, acquisitions, and meeting the needs of residents in long-term care facilities.

Key Dates

Keywords

Guardian Pharmacy Services, financial results, long-term care pharmacy, revenue, EBITDA, acquisitions, IPO, guidance